Skip to main content
Huntsman Cancer Institute

Why Choose Us for Bispecific Antibody Therapy

Bispecific antibody therapy is one of the most powerful new ways to use your own immune system to fight cancer. At Huntsman Cancer Institute, you have access to these treatments through BiCAP, our Bispecific Antibody for the Treatment of Cancer Access Program. BiCAP is the only program of its kind in the Mountain West, built specifically to deliver these complex therapies safely, support your local care team, and help you get back home as soon as it is safe. 

Brian Russell holding a baseball bat; beside him is a photo of him and his family

“Having access to this kind of treatment is incredible. I feel I'm getting the benefit of cutting-edge cancer treatment that truly has saved my life.”

Brian Russell
Bispecific antibody therapy patient

What Sets Us Apart

  • The only NCI-designated Comprehensive Cancer Center in the Mountain West. Our designation by the National Cancer Institute gives you access to clinical trials, emerging bispecific therapies, and earlier-line treatment options you may not find at any other regional center.
  • A team built around you. Hematologists, oncologists, advanced practice clinicians, pharmacists, infusion and inpatient nurses, social workers, and ancillary staff work together on a plan that fits your life. A standing Bispecific Antibody Committee reviews new approvals and keeps your care current.
  • One of the highest-volume bispecific programs in the region. In our first year, our team delivered more than 800 bispecific antibody doses across nine FDA-approved therapies, covering blood cancers and solid tumors.  
  • Care is designed for the people we serve. We provide expert care to the Mountain West—Utah, Colorado, Idaho, Montana, Nevada, Wyoming—and beyond. More than 4 in 10 of our bispecific patients live in rural or frontier areas, and our program is built to reach them.
Nurses give a patient a shot in her arm
  • Optimized delivery. Care is designed to help patients spend less time in the hospital when possible. Our team has built outpatient step-up dosing protocols, rapid ramp-up pathways for certain therapies, and remote home monitoring. Through Huntsman at Home™, some of your care can happen where you live.
  • A leader in bispecific research. Our myeloma and lymphoma teams help lead national consortia studying bispecific antibodies, including the U.S. Multiple Myeloma Immunotherapy Consortium and the Lymphoma Collaborative U.S. Bispecific Consortium (CUBIC). Bispecific antibody studies make up about 1 in 5 of our lymphoma clinical trial enrollments.

Extending Our Expertise to Your Home Community

Bispecific therapy works best when your local care team is part of the plan. Through BiCAP and our community partnerships, your home oncology team receives education, real-time consultation, and shared protocols so that much of your ongoing care can happen close to home. 

Bispecific Antibody for the Treatment of Cancer Access Program (BiCAP)

BiCAP is our coordinated program for delivering bispecific antibody therapy across the Mountain West. It connects hematology, oncology, pharmacy, nursing, and supportive care through a standing Bispecific Antibody Committee that sets standards for safe delivery and toxicity care. BiCAP is built around a hub-and-spoke model: Depending on your type of cancer and your treatment, your first cycle may take place at Huntsman Cancer Institute during the highest-risk period, then care transitions back to your local team as soon as possible. 

ACCESS and Project ECHO at Huntsman Cancer Institute

Through the Huntsman Cancer Institute ACCESS Network (Advancing Cancer Care Education & Specialty Support), our specialists connect with community oncology teams using the Project ECHO (Extension for Community Healthcare Outcomes) model—live, case-based virtual sessions that bring our expertise directly to the providers where you live. Early ECHO programs improved community-provider confidence in bispecific care and informed how we expand access to care to new regions and provide new therapies. 

Make an Appointment with a Bispecific Antibody Specialist

To make an appointment with a bispecific antibody therapy specialist, fill out our appointment form or call 801-587-7000. Our team will determine if your insurance covers treatment at Huntsman Cancer Institute or if you need a referral from a primary care doctor.

External providers can refer a patient using the online referral form or by calling 801-587-7000 to speak to a patient registration specialist.

Frequently Asked Questions

    A bispecific antibody is a type of immunotherapy. It is a lab-made protein that can attach to two targets at the same time: one on a cancer cell and one on your own immune cell (called a T cell). By linking the two, the bispecific brings your T cells directly to the cancer so they can destroy it.

    Unlike CAR T-cell therapy, bispecific antibodies do not require collecting and modifying your own cells. They are “off-the-shelf,” which means treatment can usually begin sooner. Bispecifics are given as a series of doses through an injection under the skin or through a vein, and treatment continues over time. 

    We carefully evaluate each patient to determine whether bispecific antibody therapy is the most appropriate option. If it is not right for you, we offer other specialized treatments and will work with you to identify the best path forward. 

    Treatments & Services

    A bispecific antibody is designed to grab a cancer cell with one “hand” and a T cell with the other. Once the two cells are connected, your T cell activates and kills the cancer cell. Different bispecifics target different markers, so your care team will choose one based on your specific cancer. 

    A diagram of a T cell and a cancer cell connected by a Bispecific T-Cell engager

    The FDA has approved bispecific antibodies to treat several cancers, and that list is growing quickly. Approved uses currently include certain types of the following:

    Your care team will review your cancer type, prior treatments, performance status, and overall health to decide whether a bispecific antibody is a good option for you. Many additional bispecifics are also available at Huntsman Cancer Institute through clinical trials, including for diseases where these therapies are not yet FDA approved

    Find a Clinical Trial

    Most major health insurance plans cover FDA-approved bispecific antibodies, but coverage details, prior authorization, and out-of-pocket costs can vary. Our financial advocates work with you and your insurer to seek coverage and answer questions about cost. For patients traveling from outside Utah, our team can also help with travel and housing planning before treatment begins. 

    Financial Advocates

    Bispecific antibodies can have serious side effects, mostly during the first few doses. Your care team will watch you closely and act quickly to treat any problems. It is important that you and your caregiver learn the signs to watch for at home. Treating side effects early helps recovery.

    • Cytokine release syndrome (CRS). CRS is the most common serious side effect. It is most likely during the step-up dosing period. Fever is the symptom and patients may have mild flu-like feelings. Our team uses standard protocols built into the electronic health record to catch and treat CRS early.
    • Neurological side effects (also called ICANS). Bispecific antibodies can cause temporary changes in how you think, speak, or move. These changes usually go away on their own. Your care team may give you medicine to help you recover.
    • Infections. Bispecifics can lower your body’s ability to fight infection. Your care team will check your immune system regularly and may prescribe preventive medicines.  
    • Low antibody levels (hypogammaglobulinemia). Some bispecifics lower the level of protective antibodies in your blood. Your care team may give you immunoglobulin (IVIG) replacement to help your body fight infection.
    • Side effects specific to your bispecific. Some bispecifics for example, those that target a marker called GPRC5D can cause changes to your mouth, skin, nails, or sense of taste. Your care team will review the side effects most relevant to the medicine you are receiving. 

    Our Supportive Oncology and Survivorship team provides support, including pain and symptom management, to patients during and after cancer treatment

    Supportive Oncology & Survivorship

    Treatment with a bispecific antibody usually follows these steps:

    • Pre-treatment evaluation. Your care team reviews your medical history and prior treatments, performs imaging and lab work, screens for infection, and confirms that bispecific therapy is right for you. Our pharmacy and provider teams plan your specific dose schedule and any preventive medicines you will need.
    • Step-up dosing. Most bispecifics begin with smaller “step-up” doses given over the first few days to weeks. This helps your body adjust and lowers the risk of severe CRS. Depending on your risk profile and the medicine, step-up doses may be given in the hospital or through one of our structured outpatient pathways.
    • Full-dose treatment. Once you tolerate the step-up doses, you receive your full dose on a regular schedule, often weekly or every two to four weeks.
    • Transition back to your community. Once you are stable, our team works directly with your local oncology team to transition your ongoing care closer to home. We send a formal handoff, share your care plan, and stay reachable by phone and telehealth if questions come up. 

    Need help navigating your care? The Cancer Learning Center is here to support you with personalized guidance, resources, and answers to your questions.

    Cancer Learning Center

    During step-up dosing, your team watches you closely for early side effects. If your symptoms are severe, you may be admitted to the hospital. Following step-up doses, ongoing doses can be given in outpatient clinics, at clinics close to home, and through our community network. Depending on your care team, telehealth follow-ups may be available so you do not have to travel for every visit. 

    When a person is diagnosed with cancer, concerns about treatments and side effects, hospital stays, and medical bills are common. Huntsman Cancer Institute offers many ways to support patients, caregivers, and loved ones.

    Wellness & Support

    Huntsman Cancer Institute helps patients and families who are traveling for treatment find nearby housing. Options include the following:

    A social worker on your care team can help you make arrangements. If your home oncology team is not able to deliver bispecifics, our ACCESS Project ECHO network, will aim to help them onboard the treatment.  

    Patient & Family Services

    Find a Bispecific Antibody Therapy Specialist

    16 Resulting Health Care Providers

    Khaled M. Alhamad, MD


    Head and Neck Cancers, Thoracic Oncology

    M. Kelsey Baron, MD


    Chronic Lymphocytic Leukemia, Hematology, Hodgkin Lymphoma, Lymphomas, Lymphoproliferative Diseases, Non-Hodgkin Lymphoma

    Allison M. Bock, MD


    Chronic Lymphocytic Leukemia, Hematology, Hodgkin Lymphoma, Non-Hodgkin Lymphoma

    Narendranath Epperla, MD, MS, FACP


    Aggressive Non-Hodgkin Lymphoma, Central Nervous System Lymphoma, Hairy Cell Leukemia, Hematology, Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Waldenstrom Macroglobulinemia

    Daniel A. Ermann, MD


    Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma

    Lindsey A. Fitzgerald, MD


    Chronic Lymphocytic Leukemia, Hematology, Hodgkin Lymphoma, Non-Hodgkin Lymphoma

    Gliceida María Galarza Fortuna, MD


    Amyloidosis, Blood and Marrow Transplantation, Multiple Myeloma

    Amandeep Godara, MBBS


    Amyloidosis, Blood and Marrow Transplantation, Cancer Immunotherapy, Hematology, Multiple Myeloma, Plasma Cell Leukemia, Plasmacytoma, Stem Cell Transplant, Waldenstrom Macroglobulinemia

    Matthew Gumbleton, MD, PhD


    Invasive Mucinous Adenocarcinoma of the Lung, Lung Cancer, Medical Oncology, Thoracic Oncology

    Ahmad S. Halwani, MD


    Chronic Lymphocytic Leukemia, Hematology, Hodgkin Lymphoma, Medical Oncology, Non-Hodgkin Lymphoma

    Boyu Hu, MD


    Cancer Immunotherapy, Chronic Lymphocytic Leukemia, Hematology, Hodgkin Lymphoma, Lymphomas, Lymphoproliferative Diseases, Non-Hodgkin Lymphoma

    Kathleen C. Kerrigan, DO


    Head and Neck Cancers, Head and Neck Surgical Oncology, Lung Cancer, Oncology, Oropharyngeal Cancer, Thoracic Oncology, Thyroid Cancer

    Patient Stories